Stock B6E SWEDISH ORPHAN BIOVITRUM AB
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Swedish Orphan Biovitrum AB Xetra

Equities

B6E

SE0000872095

Real-time Estimate Tradegate
Other stock markets
 15:59:58 2024-07-16 EDT 		5-day change 1st Jan Change
24.13 EUR 0.00% Intraday chart for Swedish Orphan Biovitrum AB 0.00% 0.00%
02:00pm Transcript : Swedish Orphan Biovitrum AB, Q2 2024 Earnings Call, Jul 16, 2024
08:00am Swedish Orphan Biovitrum AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Transcript : Swedish Orphan Biovitrum AB, Q2 2024 Earnings Call, Jul 16, 2024
Sobi Q2 2024 report: Strong delivery driven by robust portfolio performance
AQ
Swedish Orphan Biovitrum AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024
CI
Swedish Orphan Biovitrum AB Updates Earnings Guidance for the Year 2024
CI
The Board of Directors of Sobi exercises authorisation for repurchase of shares for the purpose of securing the company's commitments under incentive programmes
AQ
Invitation: Sobi's Q2 2024 report
PU
Sweden's Sobi Begins Rolling Application for Gout Treatment in US
MT
Sobi Initiates Rolling Biologics License Application to FDA for SEL-212 for the Potential Treatment of Chronic Refractory Gout
CI
Sobi initiates rolling biologics license application to FDA for SEL-212 for the potential treatment of chronic refractory gout
AQ
Sobi Wins EU Approval for Hemophilia A Drug Altuvoct
MT
European Commission Grants Sobi® Marketing Authorisation for Altuvoct? for Treatment of Haemophilia A
CI
Swedish Orphan Biovitrum : European Commission grants Sobi® Marketing Authorisation for ALTUVOCT™ for treatment of haemophilia A
PU
Swedish Orphan Biovitrum : Sobi to present new haemophilia data at ISTH 2024
PU
Swedish Orphan Biovitrum : Sobi to present new data across its haematology portfolio at the 2024 EHA congress
PU
BerGenBio ASA Enter into A Clinical Trial Agreement with the Mays Cancer Center At the University of Texas Health Science Center At San Antonio and Swedish Orphan Biovitrum AB
CI
Sobi to present new myelofibrosis data at the ASCO 2024 Annual Meeting
GL
Sobi North America Gets FDA Fast Track Designation for Rheumatic Disease Complication Treatment
DJ
Sobi Receives US FDA Fast Track Designation for Emapalumab-lzsg being investigated in Macrophage Activation Syndrome
GL
Bulletin from Sobi's Annual General Meeting (AGM)
AQ
Swedish Orphan Biovitrum AB Elects Zlatko Rihter as New Board Member
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SOBI Stock
  4. B6E Stock
  5. News Swedish Orphan Biovitrum AB